Administration of nedd8-activating enzyme inhibitor and hypomethylating agent

Abstract

The present disclosure relates to methods for the treatment of cancer in patients in recognized need of such treatment. The methods comprise administering to such a patient an NAE inhibitor or a pharmaceutically acceptable salt thereof, such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl)methyl sulfamate (I-216), and a hypomethylating agent or a pharmaceutically acceptable salt thereof, such as azacitidine or decitabine. Also disclosed are medicaments for use in the treatment of cancer.

What is claimed is: 
     
         1 . A method of treating cancer comprising, administering to a patient in need of such treatment a therapeutically effective total amount of
 an NAE inhibitor or a pharmaceutically acceptable salt thereof, and   a hypomethylating agent or a pharmaceutically acceptable salt thereof.   
     
     
         2 . The method of  claim 1 , wherein the hypomethylating agent is azacitidine or decitabine, or a pharmaceutically acceptable salt thereof. 
     
     
         3 . The method of  claim 2 , wherein the hypomethylating agent is azacitidine or a pharmaceutically acceptable salt thereof. 
     
     
         4 . The method of  claim 2 , wherein the hypomethylating agent is decitabine or a pharmaceutically acceptable salt thereof. 
     
     
         5 . The method of  claim 1 , wherein the NAE inhibitor is ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or {(1S,2S,4R)-4-(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl)methyl sulfamate, or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The method of  claim 5 , wherein the NAE inhibitor is ((1S,2S,4R)-4-(4-((15)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methy sulfamate or a pharmaceutically acceptable salt thereof. 
     
     
         7 . The method of  claim 5 , wherein the NAE inhibitor is {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl)methyl sulfamate, or a pharmaceutically acceptable salt thereof. 
     
     
         8 . The method of  claim 6 , wherein ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof is administered on Days 1, 3, and 5 of a 28-day cycle. 
     
     
         9 . The method of  claim 8 , wherein ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof is administered at a dose of about 20 mg/m 2 . 
     
     
         10 . The method of  claim 8 , wherein ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-4H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof is administered at a dose of about 30 mg/m 2 . 
     
     
         11 . The method of  claim 8 , wherein ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof is administered at a dose of about 40 mg/m 2 . 
     
     
         12 . The method of  claim 8 , wherein ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof is administered at a dose of about 50 mg/m 2 . 
     
     
         13 . The method of  claim 8 , wherein ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof is administered intravenously. 
     
     
         14 . The method of  claim 8 , wherein ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof is administered subcutaneously. 
     
     
         15 . The method of any one of  claim 1 , wherein the hypomethylating agent is azacitidine or a pharmaceutically acceptable salt thereof and is administered on Days 1, 2, 3, 4, 5, 8 and 9 of a 28-day cycle. 
     
     
         16 . The method of  claim 15 , wherein the azacitidine or pharmaceutically acceptable salt thereof is administered at a dose of about 75 mg/m 2 . 
     
     
         17 . The method of  claim 15 , wherein the azacitidine or pharmaceutically acceptable salt thereof is administered subcutaneously. 
     
     
         18 . The method of  claim 15 , wherein the azacitidine or pharmaceutically acceptable salt thereof is administered intravenously. 
     
     
         19 . The method of  claim 1 , wherein the NAE inhibitor or pharmaceutically acceptable salt thereof is administered in combination with the hypomethylating agent or pharmaceutically acceptable salt thereof in a single dosage form. 
     
     
         20 . The method of  claim 1 , wherein the NAE Inhibitor or pharmaceutically acceptable salt thereof is administered in combination with the hypomethylating agent or pharmaceutically acceptable salt thereof in separate dosage forms. 
     
     
         21 . The method of  claim 1 , wherein the cancer is a hematologic malignancy. 
     
     
         22 . The method of  claim 21 , wherein the cancer is acute myeloid leukemia (AML). 
     
     
         23 . The method of  claim 21 , wherein the cancer is myelodysplastic syndromes (MDS). 
     
     
         24 . The method of  claim 23 , wherein the myelodysplastic syndromes (MDS) are diagnosed as any of refractory anemia (RA), refractory anemia with ringed siderblasts (RARS), (refractory anemia with excess blasts (RAEB), and RAEB in transformation (RAEB-T). 
     
     
         25 . The method of  claim 24 , wherein the diagnosis is predominantly one type of myelodysplastic syndromes. 
     
     
         26 . The method of  claim 24 , wherein the diagnosis is more than one type of myelodysplastic syndromes. 
     
     
         27 . The method of  claim 21 , wherein the cancer is diagnosed as any of chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL), T-cell lymphoma, multiple myeloma (MM), Waldenstrom's macroglobulinemia, myelodysplastic syndromes (MDS), and myeloproliferative syndromes. 
     
     
         28 . The method of  claim 27 , wherein the diagnosis is predominantly one type of cancer. 
     
     
         29 . The method of  claim 27 , wherein the diagnosis is more than one type of cancer. 
     
     
         30 . A kit for treating cancer in a subject in recognized need thereof comprising:
 at least one medicament comprising at least one dose of an NAE Inhibitor or a pharmaceutically acceptable salt thereof, and   at least one medicament comprising at least one dose of a hypomethylating agent or a pharmaceutically acceptable salt thereof;   
       said kit for treating cancer further comprising dosing instructions for administering the medicaments for treatment of the subject in recognized need thereof.